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LETTERS
Guillain-Barré 
Syndrome after 
Chikungunya 
Infection
To the Editor: Chikungunya vi-
rus is an RNA alphavirus (group A 
arbovirus) in the family Togaviridae. 
The known vectors are Aedes aegypti 
and Ae. albopictus mosqitoes. Chikun-
gunya infection, after an incubation 
period of 2–10 days, has the main clin-
ical manifestations of fever, polyarth-
ralgia, and rash. Treatment consists of 
rest and medication for pain. Outcome 
is marked by incapacitating arthralgia, 
which can persist for several weeks 
or months (1). Complications are 
rare and consist of mild hemorrhage, 
myocarditis, and hepatitis (2). Neu-
rologic manifestations are less well 
known (3). Infection is conﬁ  rmed by 
the identiﬁ  cation of genomic products 
in acute-phase blood specimens, (re-
verse transcription–PCR [RT-PCR]) 
or, more recently, by serum immuno-
globulin (Ig) M or a 4-fold increase 
in other antibodies. In 2006, chikun-
gunya virus was found on Réunion Is-
land; seroprevalence on the island was 
estimated to be 38.2% among 785,000 
inhabitants (95% conﬁ  dence interval 
35.9%–40.6%) (4).
Guillain-Barré syndrome (GBS) 
is an acute inﬂ  ammatory demyelinat-
ing polyneuropathy; incidence world-
wide is 0.6–4/100,000 persons/year. 
In two thirds of patients, neuropathic 
GBS occurs after an infection (5,6). 
Cases of GBS have been de-
scribed in association with the arbo-
viruses dengue and West Nile but not 
with chikungunya virus. We report 2 
cases of acute and severe GBS related 
to infection with chikungunya virus.
The ﬁ  rst patient was a 51-year-old 
woman who in 2006 was admitted to an 
intensive care unit in Réunion Island’s 
Centre Hospitalier Departemental for 
treatment of polyradiculoneuropathy. 
Her medical history consisted of poor-
ly treated type 2 diabetes and hyper-
tension. Three weeks before hospital 
admission, she had had fever, arthral-
gia, rash, and diarrhea. One week later, 
rapidly progressing motor weakness 
and sensory disturbances developed, 
e.g., tingling in all limbs. She had fa-
cial diplegia, and her tendon reﬂ  exes 
were absent. Cerebrospinal ﬂ  uid (CSF) 
contained increased protein (1.44 g/L) 
but not increased leukocytes (1/mm3). 
Electromyography displayed typical 
signs of demyelinating sensorimotor 
neuropathy with increased distal motor 
latency and reduced motor conduction 
velocity. Sensory nerve action potential 
was absent. Antichikungunya IgM was 
found in serum at 15 days after onset 
of signs and symptoms. This serocon-
version conﬁ  rms an acute infection by 
an alphavirus. Serum genomic product 
(RT-PCR, TaqMan method) (7) was 
negative for chikungunya virus. Anti-
chikungunya IgM and IgG were also 
found in CSF.
The patient’s respiration rapidly 
deteriorated, and she required tracheal 
intubation and mechanical ventilation 
for 12 days. She was given intravenous 
immunoglobulin for 5 days (TEGE-
LINE; LBF Biomedicaments, Courta-
boeuf, France). She recovered and 
was extubated on day 12. Two months 
after onset of symptoms, the patient 
reported a satisfactory recovery; she 
was able to walk, and her sensory dis-
turbances had rapidly disappeared.
The second patient was a 48-year-
old woman who in 2006 was admitted 
to the intensive care unit in Réunion 
Island’s Centre Hospitalier Departe-
mental unit for a rapidly developing 
polyradiculoneuropathy. She had no 
relevant past medical history. Two 
weeks before her admission, she had 
been febrile and had had arthralgia 
and a rash. Later, weakness with fa-
cial diplegia and sensory disturbances 
developed, e.g., tingling in all limbs. 
Tendon reﬂ   exes were absent. CSF 
contained increased protein but not 
increased leukocytes. Electromyog-
raphy displayed signs of a peripheral 
neuropathy and evidence of a con-
duction block. At the time of hospital 
admission, antichikungunya IgM and 
IgG were detected in 2 serum samples. 
RT-PCR for chikungunya virus in se-
rum and CSF was negative.
The patient’s respiration rapidly 
deteriorated, and she required tracheal 
intubation and mechanical ventilation 
for 9 days. After receiving intravenous 
immunoglobulin for 5 days, she re-
covered quickly. Return of a produc-
tive cough and satisfactory muscle 
tone enabled her to be removed from 
mechanical ventilation on day 9.
For the 2 patients reported here, 
GBS diagnosis was based on a typi-
cal clinical acute motor and sen-
sory polyradiculoneuropathy, which 
evolved in 3 characteristic stages: 
rapid deterioration, plateau, and slow 
recovery (6). Also typical of GBS are 
normal CSF counts, increased CSF 
proteins, and electromyography data 
(peripheral neuropathy, conduction 
block). The widespread screening for 
organisms known to be associated 
with GBS produced negative results. 
However, antichikungunya IgM was 
found in serum and CSF, although 
genomic products in serum and CSF 
were negative, which was not surpris-
ing, given the brief period (4–5 days) 
of viremia (8). These ﬁ  ndings strongly 
supported a disseminated acute chi-
kungunya infection and enabled us to 
conclude that chikungunya virus was 
probably responsible for the GBS.
Epidemiologic data also support 
a causal relationship between chikun-
gunya infection and GBS. The inci-
dence rate of GBS increased ≈22% in 
2006 (26/787,000 [3.3/100,000] per-
sons) over the rate in 2005 (21/775,000 
[2.7/10,000] persons) and then declined 
to a rate closer to baseline in 2007 
(23/800,000 [2.87/100,000] persons).
These 2 cases of GBS on Réunion 
Island were related to an acute and 
documented chikungunya infection. 
In the absence of an effective treat-
ment, patients with these suspected 
infections should receive supportive 
care for classic GBS.
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Cockroaches 
(Ectobius 
vittiventris) in an 
Intensive Care Unit, 
Switzerland1
To the Editor:  Ectobius vit-
tiventris (Costa) is a ﬁ  eld-dwelling 
cockroach and 1 of 4,000 cockroach 
species worldwide (1). We describe a 
cockroach infestation of an intensive 
care unit (ICU). Successful manage-
ment required knowledge of the ecolo-
gy of cockroaches and highlighted the 
need for species-level identiﬁ  cation to 
tailor control strategies.
The University of Geneva Hospi-
tals are a 2,200-bed tertiary healthcare 
center. The 18-bed medical ICU is lo-
cated on the ground ﬂ  oor next to an 
outdoor recreational area and admits 
≈1,400 patients/year. Smoking inside 
hospital buildings by patients and 
healthcare workers (HCWs) is strictly 
prohibited. On August 25, 2006, ≈30 
cockroaches were observed in the ICU 
hiding inside oxygen masks, moving 
around on the light panels below the 
ceilings, or dropping onto intubated 
patients during the night.
An outbreak investigation was 
initiated. All work areas, including 
sinks and material stock areas, were 
thoroughly searched for cockroaches. 
External pest control experts identi-
ﬁ   ed only 1 species, E.  vittiventris, 
which had presumably entered the 
ICU through windows facing the out-
door recreational area. The investiga-
tion showed that despite verbal rec-
ommendations and being repeatedly 
forbidden to do so, HCWs had opened 
the windows secretly with screwdriv-
ers so that they could smoke dur-
ing night shifts. The infestation was 
halted within 3 days after information 
regarding the infestation was provided 
to HCWs and all windows were bolted 
shut. In contrast to measures required 
to deal with a reported infestation in a 
neonatal ICU (2), no other measures 
such as use of insecticides, review of 
the air circulation system, or changes 
in architectural structures were neces-
sary to stop the infestation reported 
here.
Cockroaches can cause 2 poten-
tially serious health problems. First, 
they may provoke allergic reactions (3). 
Second, they have been suggested as 
possible vectors of multidrug-resistant 
pathogens. In particular, cockroaches 
that live and breed in hospitals have 
higher bacterial loads than cockroaches 
in the community (4–6). Up to 98% of 
these “nosocomial” cockroaches may 
carry medically important microorgan-
isms on their external surfaces or in 
their alimentary tracts (4–9) and may 
disseminate these microorganisms by 
fecal–oral transmission.
Cockroaches are capable of har-
boring Escherichia coli (6,7), Enter-
obacter spp. (6,8,9),  Klebsiella spp. 
(6,7,9),  Pseudomonas aeruginosa 
(6,9),  Acinetobacter baumannii (2), 
other nonfermentative bacteria (7,9), 
Serratia marcescens ( 7,9),  Shigella 
spp. (6), Staphylococcus aureus (6,7), 
group A streptococci (6,7,9), Entero-
coccus  spp. (6,7),  Bacillus spp. (7), 
various fungi (6–8), and parasites and 
their cysts (6). An outbreak of extend-
ed-spectrum  β-lactamase–producing 
Klebsiella pneumoniae in a neonatal 
unit was attributed to cockroaches (2). 
Pulsed-ﬁ  eld gel electrophoresis did not 
distinguish organisms from the insects 
from those colonizing infants or caus-
ing clinical disease (2). Unlike other 
investigators, we did not cultivate the 
cockroaches (6,9).
E.  vittiventris cockroaches are 
easily confused with Blattella ger-
manica (Linnaeus) (the German or 
croton cockroach), which is probably 
the most important cockroach pest 
worldwide (1,9). In contrast to B. ger-
manica (6,9) and other species (online 
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